Literature DB >> 18849633

Intravitreal bevacizumab (Avastin) for choroidal neovascularization in angioid streaks: a case series.

M Carla Donati1, Gianni Virgili, Alessandro Bini, Fabrizio Giansanti, Emilio Rapizzi, Giovanni Giacomelli, Ugo Menchini.   

Abstract

BACKGROUND: Intravitreal (IV) bevacizumab (Avastin(R), Roche), initially used for the off-label treatment of neovascular age-related macular degeneration (AMD), has extended itself to treat various ocular pathologies such as choroidal neovascularization not associated to AMD.
METHODS: IV bevacizumab 1,25 mg (Avastin) was used in the treatment of choroidal neovascularization (CNV) in 6 eyes of 5 patients with angioid streaks. All cases had a history of photodynamic treatment (PDT) or laser treatment and all showed progressive worsening despite the use of these therapies.
RESULTS: After injection patients were followed up at nearly 2-month intervals. IV Avastin was repeated in case of recurrence. Three eyes were treated combining PDT and IV Avastin. Cases were followed up for 7-14 months. All patients needed more IV injections. Five out of 6 eyes showed an improvement of BCVA and a slight reduction of leakage and size with FA.
CONCLUSION: This small series suggests that IV Avastin might be useful in the treatment of CNV due to AS. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18849633     DOI: 10.1159/000161879

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  3 in total

1.  Intravitreal bevacizumab for choroidal neovascularization secondary to non-age-related macular degeneration.

Authors:  Masoud Salehipour; Nasser Vafi; Azade Doozande; Mehdi Yaseri
Journal:  J Ophthalmic Vis Res       Date:  2010-01

2.  Intravitreal Bevacizumab for Choroidal Neovascularization Associated with Angioid Streaks: Long-term Results.

Authors:  T Lekha; Hari Narayan Prasad; Renuka Nikit Sarwate; Manasi Patel; S Karthikeyan
Journal:  Middle East Afr J Ophthalmol       Date:  2017 Jul-Sep

3.  Angioid streaks, clinical course, complications, and current therapeutic management.

Authors:  Ilias Georgalas; Dimitris Papaconstantinou; Chrysanthi Koutsandrea; George Kalantzis; Dimitris Karagiannis; Gerasimos Georgopoulos; Ioannis Ladas
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.